Terms: = Ovarian cancer AND FOXP3, AIID, DIETER, IPEX, JM2, PIDX, XPID AND Diagnosis
6 results:
1. Prognostic value of regulatory T cells and T helper 17 cells in high grade serous ovarian carcinoma.
Marchenko S; Piwonski I; Hoffmann I; Sinn BV; Kunze CA; Monjé N; Pohl J; Kulbe H; Schmitt WD; Darb-Esfahani S; Braicu EI; von Brünneck AC; Sehouli J; Denkert C; Horst D; Jöhrens K; Taube ET
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2523-2536. PubMed ID: 35763108
[TBL] [Abstract] [Full Text] [Related]
2. Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer.
Leary A; Genestie C; Blanc-Durand F; Gouy S; Dunant A; Maulard A; Drusch F; Cheaib B; Michels J; Bentivegna E; LeFormal A; Mesnage S; Morice P; Pautier P; Khairallah AS
Cancer Immunol Immunother; 2021 Feb; 70(2):519-531. PubMed ID: 32852603
[TBL] [Abstract] [Full Text] [Related]
3. The Association of Peripheral Blood Regulatory T-Cell Concentrations With Epithelial ovarian cancer: A Brief Report.
Cannioto RA; Sucheston-Campbell LE; Hampras S; Goode EL; Knutson K; Ness R; Modugno F; Wallace P; Szender JB; Mayor P; Hong CC; Joseph JM; Friel G; Davis W; Nesline M; Eng KH; Edwards RP; Kruszka B; Schmitt K; Odunsi K; Moysich KB
Int J Gynecol Cancer; 2017 Jan; 27(1):11-16. PubMed ID: 27759594
[TBL] [Abstract] [Full Text] [Related]
4. CD25 identifies a subset of CD4⁺foxp3⁻ TIL that are exhausted yet prognostically favorable in human ovarian cancer.
deLeeuw RJ; Kroeger DR; Kost SE; Chang PP; Webb JR; Nelson BH
Cancer Immunol Res; 2015 Mar; 3(3):245-53. PubMed ID: 25480168
[TBL] [Abstract] [Full Text] [Related]
5. CD4 (+)CD25 (+)foxp3 (+) regulatory T cells and hematologic malignancies.
Kelley TW; Parker CJ
Front Biosci (Schol Ed); 2010 Jun; 2(3):980-92. PubMed ID: 20515837
[TBL] [Abstract] [Full Text] [Related]
6. The impact of T-cell immunity on ovarian cancer outcomes.
Nelson BH
Immunol Rev; 2008 Apr; 222():101-16. PubMed ID: 18363996
[TBL] [Abstract] [Full Text] [Related]
